Cancer Diagnostic Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Cancer Diagnostic Market : By Components (Instruments, Reagents and Kits, Accessories), By Test Types (Genetic Testing, Liquid Biopsy, Conventional Tests, Biopsy, Others), By Sample Type (Blood, Urine, Tissue, Others), By Indication (Colorectal Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Others), By End User (Hospitals and Clinics, Diagnostic Centers, Academic and Research Institutes, Others), and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

1. Executive Summary
2. Global Cancer Diagnostic Market Introduction
2.1. Global Cancer Diagnostic – Taxonomy
2.2. Global Cancer Diagnostic –Definitions
2.2.1. By Components
2.2.2. By Test Types
2.2.3. By Sample Type
2.2.4. By Indication
2.2.5. By End User
2.2.6. By Region
3. Global Cancer Diagnostic Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cancer Diagnostic Dynamic Factors – Impact Analysis
3.6. Global Cancer Diagnostic – Competition Landscape
4. Global Cancer Diagnostic Analysis,2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Cancer Diagnostic, By Components, 2017–2021and Forecast, 2022–2028 (Revenue, USD Mn)
5.1. Instruments
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Reagents and Kits
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Accessories
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Cancer Diagnostic, By Test Types, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
6.1. Genetic Testing
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Liquid Biopsy
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Conventional Tests
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Biopsy
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Cancer Diagnostic Forecast, By Sample Type,2017–2021and Forecast, 2022–2028 (Revenue, USD Mn)
7.1. Blood
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Urine
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Tissue
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Cancer Diagnostic Forecast, By Indication, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
8.1. Colorectal Cancer
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Ovarian Cancer
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Lung Cancer
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Breast Cancer
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Prostate Cancer
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Cervical Cancer
8.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.6.3. Market Opportunity Analysis
8.7. Others
8.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.7.3. Market Opportunity Analysis
9. Global Cancer Diagnostic, By End User, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
9.1. Hospitals and Clinics
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Diagnostic Centers
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Academic and Research Institutes
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Others
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
10. Global Cancer Diagnostic Forecast, By Region, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
10.1. North America
10.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Region, 2022 – 2028
11. North America Cancer DiagnosticAnalysis,2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
11.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Instruments
11.1.2. Reagents and Kits
11.1.3. Accessories
11.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Genetic Testing
11.2.2. Liquid Biopsy
11.2.3. Conventional Tests
11.2.4. Biopsy
11.2.5. Others
11.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Blood
11.3.2. Urine
11.3.3. Tissue
11.3.4. Others
11.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Colorectal Cancer
11.4.2. Ovarian Cancer
11.4.3. Lung Cancer
11.4.4. Breast Cancer
11.4.5. Prostate Cancer
11.4.6. Cervical Cancer
11.4.7. Others
11.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Hospitals and Clinics
11.5.2. Diagnostic Centers
11.5.3. Academic and Research Institutes
11.5.4. Others
11.6. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. USA
11.6.2. Canada
11.7. North America Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Country, 2022 – 2028
11.8. North America Cancer Diagnostic Dynamics – Trends
12. Europe Cancer Diagnostic Analysis, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
12.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Instruments
12.1.2. Reagents and Kits
12.1.3. Accessories
12.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Genetic Testing
12.2.2. Liquid Biopsy
12.2.3. Conventional Tests
12.2.4. Biopsy
12.2.5. Others
12.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Blood
12.3.2. Urine
12.3.3. Tissue
12.3.4. Others
12.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Colorectal Cancer
12.4.2. Ovarian Cancer
12.4.3. Lung Cancer
12.4.4. Breast Cancer
12.4.5. Prostate Cancer
12.4.6. Cervical Cancer
12.4.7. Others
12.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Hospitals and Clinics
12.5.2. Diagnostic Centers
12.5.3. Academic and Research Institutes
12.5.4. Others
12.6. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End Userand Country, 2022 – 2028
12.8. Europe Cancer Diagnostic Dynamics – Trends
13. Asia-Pacific Cancer Diagnostic Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Instruments
13.1.2. Reagents and Kits
13.1.3. Accessories
13.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Genetic Testing
13.2.2. Liquid Biopsy
13.2.3. Conventional Tests
13.2.4. Biopsy
13.2.5. Others
13.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Blood
13.3.2. Urine
13.3.3. Tissue
13.3.4. Others
13.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Colorectal Cancer
13.4.2. Ovarian Cancer
13.4.3. Lung Cancer
13.4.4. Breast Cancer
13.4.5. Prostate Cancer
13.4.6. Cervical Cancer
13.4.7. Others
13.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Hospitals and Clinics
13.5.2. Diagnostic Centers
13.5.3. Academic and Research Institutes
13.5.4. Others
13.6. Country Analysis2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Country,2022 – 2028
13.8. Asia-Pacific Cancer Diagnostic Dynamics – Trends
14. Latin America Cancer Diagnostic Analysis,2017 – 2021 and Forecast, 2022–2028(Revenue, USD Mn)
14.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Instruments
14.1.2. Reagents and Kits
14.1.3. Accessories
14.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Genetic Testing
14.2.2. Liquid Biopsy
14.2.3. Conventional Tests
14.2.4. Biopsy
14.2.5. Others
14.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Blood
14.3.2. Urine
14.3.3. Tissue
14.3.4. Others
14.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Colorectal Cancer
14.4.2. Ovarian Cancer
14.4.3. Lung Cancer
14.4.4. Breast Cancer
14.4.5. Prostate Cancer
14.4.6. Cervical Cancer
14.4.7. Others
14.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Hospitals and Clinics
14.5.2. Diagnostic Centers
14.5.3. Academic and Research Institutes
14.5.4. Others
14.6. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Rest of Latin America
14.7. Latin America Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Country, 2022 – 2028
14.8. Latin America Cancer Diagnostic Dynamics – Trends
15. Middle East and Africa Cancer Diagnostic Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
15.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.1.1. Instruments
15.1.2. Reagents and Kits
15.1.3. Accessories
15.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Genetic Testing
15.2.2. Liquid Biopsy
15.2.3. Conventional Tests
15.2.4. Biopsy
15.2.5. Others
15.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Blood
15.3.2. Urine
15.3.3. Tissue
15.3.4. Others
15.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Colorectal Cancer
15.4.2. Ovarian Cancer
15.4.3. Lung Cancer
15.4.4. Breast Cancer
15.4.5. Prostate Cancer
15.4.6. Cervical Cancer
15.4.7. Others
15.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Hospitals and Clinics
15.5.2. Diagnostic Centers
15.5.3. Academic and Research Institutes
15.5.4. Others
15.6. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Country, 2022 – 2028
15.8. MEA Cancer Diagnostic Dynamics – Trends
16. Competition Landscape 
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Components& Service Test Types, Key Developments, Strategies, and SWOT Analysis)
16.2.1. Abbott Laboratories
16.2.2. Siemens Healthineers
16.2.3. Becton, Dickinson and Company
16.2.4. Illumina, Inc.
16.2.5. Bio-Rad Laboratories
16.2.6. Roche Diagnostics
16.2.7. Qiagen N.V.
16.2.8. ThermoFisher Scientific, Inc.
16.2.9. Quest Diagnostics
16.2.10. bioMérieux SA
16.2.11. MDNA Life Sciences, Inc.
17. Research Methodology
18. Key Assumptions and Acronyms

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Company Profile

 

  • Abbott Laboratories
  • Siemens Healthineers
  • Becton, Dickinson and Company
  • Illumina, Inc.
  • Bio-Rad Laboratories
  • Roche Diagnostics
  • Qiagen N.V.
  • ThermoFisher Scientific, Inc.
  • Quest Diagnostics
  • bioMérieux SA
  • MDNA Life Sciences, Inc.

Description

1. Executive Summary
2. Global Cancer Diagnostic Market Introduction
2.1. Global Cancer Diagnostic – Taxonomy
2.2. Global Cancer Diagnostic –Definitions
2.2.1. By Components
2.2.2. By Test Types
2.2.3. By Sample Type
2.2.4. By Indication
2.2.5. By End User
2.2.6. By Region
3. Global Cancer Diagnostic Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Cancer Diagnostic Dynamic Factors – Impact Analysis
3.6. Global Cancer Diagnostic – Competition Landscape
4. Global Cancer Diagnostic Analysis,2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Cancer Diagnostic, By Components, 2017–2021and Forecast, 2022–2028 (Revenue, USD Mn)
5.1. Instruments
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Reagents and Kits
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Accessories
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Cancer Diagnostic, By Test Types, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
6.1. Genetic Testing
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Liquid Biopsy
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Conventional Tests
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Biopsy
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Cancer Diagnostic Forecast, By Sample Type,2017–2021and Forecast, 2022–2028 (Revenue, USD Mn)
7.1. Blood
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Urine
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Tissue
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Cancer Diagnostic Forecast, By Indication, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
8.1. Colorectal Cancer
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Ovarian Cancer
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Lung Cancer
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Breast Cancer
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Prostate Cancer
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Cervical Cancer
8.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.6.3. Market Opportunity Analysis
8.7. Others
8.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.7.3. Market Opportunity Analysis
9. Global Cancer Diagnostic, By End User, 2017 – 2021 and Forecast, 2021 – 2027 (Revenue, USD Mn)
9.1. Hospitals and Clinics
9.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Diagnostic Centers
9.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Academic and Research Institutes
9.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Others
9.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
10. Global Cancer Diagnostic Forecast, By Region, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
10.1. North America
10.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.1.3. Market Opportunity Analysis
10.2. Europe
10.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.2.3. Market Opportunity Analysis
10.3. Asia-Pacific
10.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.3.3. Market Opportunity Analysis
10.4. Latin America
10.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.4.3. Market Opportunity Analysis
10.5. Middle East and Africa
10.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
10.5.3. Market Opportunity Analysis
10.6. Global Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Region, 2022 – 2028
11. North America Cancer DiagnosticAnalysis,2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
11.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Instruments
11.1.2. Reagents and Kits
11.1.3. Accessories
11.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Genetic Testing
11.2.2. Liquid Biopsy
11.2.3. Conventional Tests
11.2.4. Biopsy
11.2.5. Others
11.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Blood
11.3.2. Urine
11.3.3. Tissue
11.3.4. Others
11.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.4.1. Colorectal Cancer
11.4.2. Ovarian Cancer
11.4.3. Lung Cancer
11.4.4. Breast Cancer
11.4.5. Prostate Cancer
11.4.6. Cervical Cancer
11.4.7. Others
11.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.5.1. Hospitals and Clinics
11.5.2. Diagnostic Centers
11.5.3. Academic and Research Institutes
11.5.4. Others
11.6. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.6.1. USA
11.6.2. Canada
11.7. North America Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Country, 2022 – 2028
11.8. North America Cancer Diagnostic Dynamics – Trends
12. Europe Cancer Diagnostic Analysis, 2017–2021and Forecast, 2022–2028(Revenue, USD Mn)
12.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Instruments
12.1.2. Reagents and Kits
12.1.3. Accessories
12.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Genetic Testing
12.2.2. Liquid Biopsy
12.2.3. Conventional Tests
12.2.4. Biopsy
12.2.5. Others
12.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Blood
12.3.2. Urine
12.3.3. Tissue
12.3.4. Others
12.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Colorectal Cancer
12.4.2. Ovarian Cancer
12.4.3. Lung Cancer
12.4.4. Breast Cancer
12.4.5. Prostate Cancer
12.4.6. Cervical Cancer
12.4.7. Others
12.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.5.1. Hospitals and Clinics
12.5.2. Diagnostic Centers
12.5.3. Academic and Research Institutes
12.5.4. Others
12.6. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.6.1. Germany
12.6.2. UK
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Russia
12.6.7. Poland
12.6.8. Rest of Europe
12.7. Europe Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End Userand Country, 2022 – 2028
12.8. Europe Cancer Diagnostic Dynamics – Trends
13. Asia-Pacific Cancer Diagnostic Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
13.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Instruments
13.1.2. Reagents and Kits
13.1.3. Accessories
13.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Genetic Testing
13.2.2. Liquid Biopsy
13.2.3. Conventional Tests
13.2.4. Biopsy
13.2.5. Others
13.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Blood
13.3.2. Urine
13.3.3. Tissue
13.3.4. Others
13.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Colorectal Cancer
13.4.2. Ovarian Cancer
13.4.3. Lung Cancer
13.4.4. Breast Cancer
13.4.5. Prostate Cancer
13.4.6. Cervical Cancer
13.4.7. Others
13.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.5.1. Hospitals and Clinics
13.5.2. Diagnostic Centers
13.5.3. Academic and Research Institutes
13.5.4. Others
13.6. Country Analysis2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. ASEAN
13.6.5. Australia & New Zealand
13.6.6. Rest of Asia-Pacific
13.7. Asia-Pacific Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Country,2022 – 2028
13.8. Asia-Pacific Cancer Diagnostic Dynamics – Trends
14. Latin America Cancer Diagnostic Analysis,2017 – 2021 and Forecast, 2022–2028(Revenue, USD Mn)
14.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.1. Instruments
14.1.2. Reagents and Kits
14.1.3. Accessories
14.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.2.1. Genetic Testing
14.2.2. Liquid Biopsy
14.2.3. Conventional Tests
14.2.4. Biopsy
14.2.5. Others
14.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.3.1. Blood
14.3.2. Urine
14.3.3. Tissue
14.3.4. Others
14.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.4.1. Colorectal Cancer
14.4.2. Ovarian Cancer
14.4.3. Lung Cancer
14.4.4. Breast Cancer
14.4.5. Prostate Cancer
14.4.6. Cervical Cancer
14.4.7. Others
14.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.5.1. Hospitals and Clinics
14.5.2. Diagnostic Centers
14.5.3. Academic and Research Institutes
14.5.4. Others
14.6. Country Analysis 2017–2021and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Argentina
14.6.4. Rest of Latin America
14.7. Latin America Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Country, 2022 – 2028
14.8. Latin America Cancer Diagnostic Dynamics – Trends
15. Middle East and Africa Cancer Diagnostic Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
15.1. Components Analysis 2017–2021and Forecast 2022 – 2028by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
15.1.1. Instruments
15.1.2. Reagents and Kits
15.1.3. Accessories
15.2. Test Types Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.2.1. Genetic Testing
15.2.2. Liquid Biopsy
15.2.3. Conventional Tests
15.2.4. Biopsy
15.2.5. Others
15.3. Sample Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.3.1. Blood
15.3.2. Urine
15.3.3. Tissue
15.3.4. Others
15.4. Indication Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.4.1. Colorectal Cancer
15.4.2. Ovarian Cancer
15.4.3. Lung Cancer
15.4.4. Breast Cancer
15.4.5. Prostate Cancer
15.4.6. Cervical Cancer
15.4.7. Others
15.5. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
15.5.1. Hospitals and Clinics
15.5.2. Diagnostic Centers
15.5.3. Academic and Research Institutes
15.5.4. Others
15.6. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
15.6.1. Gulf Cooperation Council (GCC) Countries
15.6.2. Israel
15.6.3. South Africa
15.6.4. Rest of MEA
15.7. MEA Cancer Diagnostic – Opportunity Analysis Index, By Components, Test Types, Sample Type, Indication, End User and Country, 2022 – 2028
15.8. MEA Cancer Diagnostic Dynamics – Trends
16. Competition Landscape 
16.1. Strategic Dashboard of Top Market Players
16.2. Company Profiles (Introduction, Financial Analysis, Components& Service Test Types, Key Developments, Strategies, and SWOT Analysis)
16.2.1. Abbott Laboratories
16.2.2. Siemens Healthineers
16.2.3. Becton, Dickinson and Company
16.2.4. Illumina, Inc.
16.2.5. Bio-Rad Laboratories
16.2.6. Roche Diagnostics
16.2.7. Qiagen N.V.
16.2.8. ThermoFisher Scientific, Inc.
16.2.9. Quest Diagnostics
16.2.10. bioMérieux SA
16.2.11. MDNA Life Sciences, Inc.
17. Research Methodology
18. Key Assumptions and Acronyms

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX